Sign in to view content

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD

Robert L. Avery, MD

Video
Published 2025

Related

Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Suprachoroidally delivered gene therapy via non-viral DNA nanoparticles
Christine Kay, MD
On Demand Cases, Courses, and Papers
2019
AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Updates from the Field
2020

Category: AMD-Neovascular

See more